Clinical Trial Update: LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating LMB-2 immunotoxin and vaccine therapy for patients with unresectable metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-melanoma Skin Cancer

Drugs mentioned

• LMB-2 immunotoxin (LMB-2 immunotoxin)
• Vaccine therapy

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Melanoma (Skin), Non-melanomatous Skin Cancer | Phase 2 | Status: COMPLETED